Fast neutron radiotherapy and boron neutron capture therapy: application to a human melanoma test system

Bull Cancer Radiother. 1996:83 Suppl:191s-7s. doi: 10.1016/0924-4212(96)84911-5.

Abstract

Fast neutron radiotherapy has proven to be an effective form of treatment in a selected subset of tumors (salivary gland tumors, sarcomas, and locally-advanced prostate cancer), but has not proven to be more beneficial than conventional photon irradiation for the majority of tumor types upon which it has been tested. Normal tissue tolerance limits preclude simply further escalating the neutron dose. Boron neutron capture (BNC) provides a way of selectively augmenting the radiation dose to the tumor. This process is described, and cell culture and animal model data reviewed. An irradiation configuration was developed where an enhancement of 2.10(-3) for 1 microgram of 10B per gram of tissue was achieved. This is similar to the enhancement achievable in the center of a 20 x 20 cm field envisioned for future applications such as metastases in the brain. A boron concentration of 50 micrograms per gram of tumor tissue leads to a 10% increase in the delivered physical dose in this scenario. The first human test of BNC enhancement of a fast neutron radiotherapy beam using pharmacologically-acceptable doses of orally-administered, 10B-enriched, L-paraboronophenylalanine is reported. An enhancement of tumor response was demonstrated for a melanoma skin nodule test system. Boron levels achieved in blood, skin, and tumors are presented. Future research plans are discussed.

MeSH terms

  • Administration, Oral
  • Boron Compounds / blood
  • Boron Compounds / therapeutic use
  • Boron Neutron Capture Therapy*
  • Dose-Response Relationship, Radiation
  • Fast Neutrons*
  • Humans
  • Melanoma / blood
  • Melanoma / radiotherapy*
  • Radiotherapy Dosage
  • Radiotherapy, High-Energy / methods*
  • Skin Neoplasms / blood
  • Skin Neoplasms / radiotherapy*

Substances

  • Boron Compounds